AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31990246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin C, thiamine and hydrocortisone
Number of subjects: 100
Study 31990246 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (control group)
Number of subjects: 100
Study 30925157 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate availability
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclampsia, stroke, or hypertensive disorder of pregnancy causing intensive care admission or maternal death
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclampsia cases by age
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Rates of eclampsia
Number of subjects: 536233
Study 30925157 — intervention group
Group type: EXPERIMENTAL
Intervention: First eclamptic fits
Number of subjects: 536233
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg/day) for 4 weeks instead of ethambutol
Number of subjects: 429
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg/day) for 2 weeks instead of ethambutol
Number of subjects: 429
Study 28193240 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol)
Number of subjects: 429
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Total adverse events (AEs) and serious AEs
Number of subjects: 429
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum culture conversion rate on solid media after 2 months
Number of subjects: 429
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to sputum culture conversion on liquid and solid media
Number of subjects: 429
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure rate
Number of subjects: 429
Study 28193240 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment success rate
Number of subjects: 429
Study 27101551 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission pro-adrenomedullin (proADM)
Number of subjects: 753
Study 27101551 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission pro-atrial natriuretic peptide (proANP)
Number of subjects: 753
Study 24626264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracentesis
Number of subjects: 160
Study 24626264 — intervention group
Group type: COMPARATOR
Intervention: Thoracentesis without ultrasound guidance
Number of subjects: 160
Study 22424813 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular visits to a primary care provider (PCP) at least once per year
Number of subjects: 16893
Study 22424813 — intervention group
Group type: COMPARATOR
Intervention: No regular visits to a primary care provider (PCP)
Number of subjects: 16893
Study 19053944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 i.u.)
Number of subjects: 40
Study 19053944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17202116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 73
Study 17202116 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement
Number of subjects: 73
Study 16086931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medications
Number of subjects: 11958
Study 11981766 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial Lipiodol chemoembolization (variable dose of cisplatin in Lipiodol and gelatin-sponge particles, median 4.5 courses per patient)
Number of subjects: 80
Study 11981766 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (control group)
Number of subjects: 80
Study 9818107 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine (8 mg)
Number of subjects: 60
Study 9818107 — intervention group
Group type: COMPARATOR
Intervention: 1% hyperbaric bupivacaine (8 mg)
Number of subjects: 60
Study 7543348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg/day (once daily)
Number of subjects: 384
Study 7543348 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day (50 mg t.i.d)
Number of subjects: 384
Study 7543348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap
Number of subjects: 384
Study 7543348 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 384
Study 30926298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix® vaccine
Number of subjects: 0
Study 30926298 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil® vaccine
Number of subjects: 0
Study 30926298 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vaccine types
Number of subjects: 0
Study 29962179 — intervention group
Group type: COMPARATOR
Intervention: High Intensity Resistance Training (HIRT) at 70% of One‐Repetition Maximum (1‐RM)
Number of subjects: 18
Study 29962179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity Resistance Training with Blood Flow Restriction (LIRT + BFR) at 30% of 1‐RM with BFR
Number of subjects: 18
Study 29962179 — intervention group
Group type: COMPARATOR
Intervention: Low Intensity Resistance Training (LIRT) at 30% of 1‐RM
Number of subjects: 18
Study 27081856 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation context (primed participants knew they were being evaluated)
Number of subjects: 0
Study 27081856 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed Evaluation context (primed participants knew they were being evaluated and were instructed to make a positive impression)
Number of subjects: 0
Study 27081856 — intervention group
Group type: COMPARATOR
Intervention: Control context (primed participants did not know they were being evaluated)
Number of subjects: 0
Study 27081856 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed Evaluation context
Number of subjects: 0
Study 25302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea hull fibre (7 g)
Number of subjects: 15
Study 25302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein (10 g)
Number of subjects: 15
Study 25302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein (10 g) plus hull fibre (7 g)
Number of subjects: 15
Study 25302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow peas (406 g)
Number of subjects: 15
Study 25302637 — intervention group
Group type: COMPARATOR
Intervention: Control (noodles and tomato sauce)
Number of subjects: 15
Study 25302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein plus fibre
Number of subjects: 15
Study 25302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow peas
Number of subjects: 15
Study 22172242 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2201
Study 22172242 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 2201
Study 19780738 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline capsules 100 mg twice daily plus triple sulfa vaginal cream once daily for ten days
Number of subjects: 80
Study 19780738 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline capsules 100 mg twice daily and triple sulfa vaginal cream once daily plus vitamin C tablets 250 mg once daily for ten days
Number of subjects: 80
Study 17206698 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention program consisting of nine weekly sessions, alternating lectures and group therapy sessions.
Number of subjects: 44
Study 17206698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 44
Study 17206698 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention program.
Number of subjects: 44
Study 15315180 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (6 mg/kg/h)
Number of subjects: 40
Study 15315180 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1%-2%)
Number of subjects: 40
Study 11317113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobics
Number of subjects: 59
Study 11317113 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 59
Study 11317113 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle training on devices
Number of subjects: 59
Study 11317113 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 9257791 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen nasal challenge
Number of subjects: 21
Study 8285592 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in symptomatic patients with greater than 70% stenosis (NASCET, ECST)
Number of subjects: 0
Study 8285592 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in asymptomatic patients (Mayo asymptomatic trial, Carotid Artery Stenosis with Asymptomatic Narrowing: Operation Versus Aspirin trial, VA Asymptomatic Trial)
Number of subjects: 0
Study 8285592 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic patients)
Number of subjects: 0
Study 3605164 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist intervention
Number of subjects: 200
Study 3605164 — intervention group
Group type: COMPARATOR
Intervention: No checklist intervention (Control)
Number of subjects: 200
Study 29473908 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine-l-tartrate 1500 mg per day
Number of subjects: 0
Study 29473908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isonitrogenous)
Number of subjects: 0
Study 27328737 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.15 mg·kg(‐1) IV plus sham acupuncture
Number of subjects: 120
Study 27328737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at P6 bilaterally and CV13 plus 2 ml of normal saline IV
Number of subjects: 120
Study 27328737 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone group
Number of subjects: 120
Study 27328737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 120
Study 25796362 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC (Computed Tomographic Colonography)
Number of subjects: 5384
Study 25796362 — intervention group
Group type: COMPARATOR
Intervention: Barium enema
Number of subjects: 5384
Study 25796362 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 5384
Study 25796362 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC
Number of subjects: 5384
Study 23780705 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lapse context (talking with friends, angry)
Number of subjects: 551
Study 23780705 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lapse context (social)
Number of subjects: 551
Study 23780705 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lapse context (alone)
Number of subjects: 551
Study 23780705 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lapse context (with spouse, angry)
Number of subjects: 551
Study 23780705 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lapse context (with smoking spouse)
Number of subjects: 551
Study 20959067 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ICTP
Number of subjects: 110
Study 20959067 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BAP
Number of subjects: 110
Study 20959067 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint detection of ICTP and BAP
Number of subjects: 110
Study 20959067 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BAP in patients with multiple B.M (lesions>=3)
Number of subjects: 110
Study 20959067 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BAP in patients with mixed pattern
Number of subjects: 110
Study 18371470 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 2951
Study 18371470 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 2951
Study 16162714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 14513588 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of immunoglobulin yolk antibodies (IgY) spray (n = 9)
Number of subjects: 24
Study 14513588 — intervention group
Group type: COMPARATOR
Intervention: 0.15% chlorhexidine (CH) spray (positive control group, n = 9)
Number of subjects: 24
Study 14513588 — intervention group
Group type: COMPARATOR
Intervention: Placebo phosphate buffered saline (PBS) spray (negative control group, n = 6)
Number of subjects: 24
Study 10526263 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with cisplatin (200 mg) and epirubicin (120 mg) via the external carotid artery
Number of subjects: 131
Study 10526263 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy (46 grays)
Number of subjects: 131
Study 10526263 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative quality of life
Number of subjects: 131
Study 8722937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin
Number of subjects: 0
Study 8722937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral teicoplanin
Number of subjects: 0
Study 8722937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fusidic acid
Number of subjects: 0
Study 8722937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 0
Study 1841548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 40
Study 1841548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 7048923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 25
Study 7048923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30636072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-(2-hydroxyethyl)-2-imidazolidinone (HEI)
Number of subjects: 0
Study 30636072 — intervention group
Group type: COMPARATOR
Intervention: Control without HEI
Number of subjects: 0
Study 29873727 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilpaterol hydrochloride (ZH) supplementation (90 mg.d‐1 per steer for 20 d)
Number of subjects: 56
Study 29873727 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 56
Study 29873727 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilpaterol hydrochloride (ZH) supplementation
Number of subjects: 56
Study 29873727 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance energy intake (MA)
Number of subjects: 56
Study 26890767 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized computer-assisted needs assessment
Number of subjects: 227
Study 25266518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) for 36 hours
Number of subjects: 18
Study 25266518 — intervention group
Group type: COMPARATOR
Intervention: Sleep Deprivation (SD)
Number of subjects: 18
Study 21918977 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum CA-125 levels above 30 U/ml
Number of subjects: 657
Study 20113825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (1 year of treatment, given as neoadjuvant and adjuvant treatment)
Number of subjects: 235
Study 20113825 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab (control group)
Number of subjects: 235
Study 17331803 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group (10% weight loss requirement)
Number of subjects: 100
Study 17331803 — intervention group
Group type: COMPARATOR
Intervention: Non-weight loss group (no weight loss requirements)
Number of subjects: 100
Study 15471363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (60 mg/day p.o. for four weeks)
Number of subjects: 0
Study 15471363 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects or untreated MS patients)
Number of subjects: 0
Study 11531934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1alpha‐hydroxyvitamin D3 + sequential combined HRT + calcium supplement
Number of subjects: 240
Study 11531934 — intervention group
Group type: COMPARATOR
Intervention: sequential combined HRT + calcium supplement
Number of subjects: 240
Study 9762781 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective respiratory device (RD) with a P2 filter
Number of subjects: 26
Study 9762781 — intervention group
Group type: COMPARATOR
Intervention: No respiratory device (control)
Number of subjects: 26
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (ST) imaging
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Redistribution (RD) imaging
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinjection (RI) imaging
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual observer measurement of ST-RD
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual observer measurement of ST-RI
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual observer measurement of RD-RI
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple observer scores for ST-RD
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple observer scores for ST-RI
Number of subjects: 396
Study 8151382 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple observer scores for RD-RI
Number of subjects: 396
Study 3071594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (standardized intensive drug treatment)
Number of subjects: 10940
Study 3071594 — intervention group
Group type: COMPARATOR
Intervention: Referred care (usual community care)
Number of subjects: 10940
Study 30566030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Number of subjects: 61
Study 30566030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29781109 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital change in heart rate
Number of subjects: 7141
Study 29781109 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital change in systolic blood pressure (SBP)
Number of subjects: 7141
Study 29781109 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital change in rate pressure product (RPP)
Number of subjects: 7141
Study 29781109 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 7141
Study 26901263 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE training (10-session DVD format)
Number of subjects: 279
Study 26901263 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE training (20-session computer-based format)
Number of subjects: 279
Study 26901263 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo auditory training (10 hours of digitized books listening)
Number of subjects: 279
Study 26901263 — intervention group
Group type: COMPARATOR
Intervention: Educational counseling (control group)
Number of subjects: 279
Study 24886626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet supplemented with extra-virgin olive oil
Number of subjects: 7216
Study 24886626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet supplemented with total olive oil
Number of subjects: 7216
Study 24886626 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline total olive oil consumption
Number of subjects: 7216
Study 24886626 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil consumption increase by 10 g/d
Number of subjects: 7216
Study 24886626 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 7216
Study 23296557 — intervention group
Group type: EXPERIMENTAL
Intervention: ALMI approach
Number of subjects: 47
Study 23296557 — intervention group
Group type: COMPARATOR
Intervention: Bauer approach
Number of subjects: 47
Study 23296557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 47
Study 20157326 — intervention group
Group type: EXPERIMENTAL
Intervention: LKF-enriched bread (lupin)
Number of subjects: 88
Study 20157326 — intervention group
Group type: COMPARATOR
Intervention: Control (white bread)
Number of subjects: 88
Study 18408580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral C2 monitoring with high range (1600-1800 ng/mL)
Number of subjects: 87
Study 18408580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral C2 monitoring with intermediate range (1400-1600 ng/mL)
Number of subjects: 87
Study 18408580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral C2 monitoring with low range (1200-1400 ng/mL)
Number of subjects: 87
Study 18408580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate C2 range in cohort B
Number of subjects: 87
Study 18408580 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral C2 monitoring (all groups)
Number of subjects: 87
Study 15816467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM) administered perioperatively, initiated 7 days before operation and continued until 10 days after surgery.
Number of subjects: 49
Study 15816467 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cimetidine treatment).
Number of subjects: 49
Study 15816467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM) treatment.
Number of subjects: 49
Study 12459936 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily
Number of subjects: 610
Study 12459936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 12459936 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 400-800 mg
Number of subjects: 610
Study 12459936 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 610
Study 10379611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide eye drops applied three times daily for 3 days
Number of subjects: 30
Study 10379611 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation applied according to the same protocol
Number of subjects: 30
Study 8540451 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker group (n = 58)
Number of subjects: 116
Study 8540451 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 58)
Number of subjects: 116
Study 1907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (85 patients)
Number of subjects: 161
Study 1907662 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (76 patients)
Number of subjects: 161